Proteros biostructures GmbH, a Munich, Germany-based contract research organization focused on early-stage drug discovery, received a minority investment from Inflexion.
With the support of Inflexion as a minority investor, the company aims to further strengthen its footprint in the US both organically and through potential acquisitions, drive sustainable growth across all of its Business Units such as, Cryo-EM, fit for purpose Biologics and Proteins, as well as integrated Discovery Solutions services and further strengthen overall value propositions for its more than 200 Biotech and Pharma customers, as a premium discovery provider for complex projects and targets.
Led by Dr. Torsten Neuefeind, founder and CEO, Proteros is a privately-held company with expertise in structure-based drug discovery powered by discovery engine tailored to unlock even the most technically challenging disease-relevant drug targets. The company provides small molecule drug discovery services and its comprehensive enabling technology platforms, coupled with roots to Nobel Prize winning science and the Max Planck Institute of Biochemistry, have enabled prominent contributions to several lead optimization programs and clinical-stage compounds.
The transaction is subject to customary regulatory approvals and is expected to close in Q1 2023.
FinSMEs
09/01/2023